Mylan N.V. announced the U.S. launch of Caspofungin Acetate for Injection, one of the first generic versions of Merck’s Cancidas. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this antifungal which has multiple indications.
Caspofungin Acetate for Injection had U.S. sales of approximately $24 million for the 12 months ending July 31, 2017, according to QuintilesIMS.
Currently, Mylan has 228 ANDAs pending FDA approval, representing approximately $100 billion in annual brand sales. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $45.5 billion in annual brand sales, for the 12 months ending July 31, 2017, according to QuintilesIMS. Currently, one out of every 13 prescriptions filled in the U.S.—brand-name or generic—is a Mylan product.
Caspofungin Acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for:
- Empirical therapy for presumed fungal infections in febrile, neutropenic patients.
- Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections.
- Treatment of esophageal candidiasis.
- Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
Mylan is a global pharmaceutical company providing 7 billion people access to medicine. The company offers a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend.
(Source: PR Newswire)